ClinicalTrials.gg
Active, not recruitingNCT05321420ELEVATEUpdated Oct 16, 2025

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by PureTech. Active, not recruiting at 103 sites in 14 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by PureTech · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Planned enrollment
9th of 21
240 · median 89
Started
2022
the only one that year
Phase 2
6 of 21
none open now
Registered
17th of 21
by date
Lead sponsor
2 of 21
PureTech

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 9th largest by planned enrollment, is the only one that started in 2022, is one of 6 in phase 2, and was the 17th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.

Read the detailed description

This study is a randomized, double-blind, being conducted at centers globally to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in 240 treatment naïve adult patients with IPF ≥ 40 years in age. Patients will be randomized in a ratio of 1:1:1:1 to receive treatment of LYT-100, pirfenidone, or placebo to be taken daily for up to 183 days (26 week treatment period) with the primary outcome of Rate of decline in Forced Vital Capacity (FVC; in mL) over 26 weeks. Secondary endpoints, including spirometry, inflammatory biomarkers, and patient-reported outcomes will also be evaluated.

After completion of the double-blind period of the study, patients may participate in a long-term extension to evaluate tolerability and long-term safety. Patients receiving LYT-100 in the double-blind period will continue the dose throughout the long-term extension. Patients receiving pirfenidone or placebo in the double-blind period will be re-randomized in a 1:1 ratio to receive LYT-100 550mg or 825mg TID dose throughout the long-term extension.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • IPF
  • lung fibrosis
  • respiratory disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Treatment naïve patients or those with \<6 months of exposure to nintedanib with physician diagnosed IPF based on ATS/ERS/JRS/ALAT 2018 guidelines
  • Idiopathic Pulmonary Fibrosis on HRCT, performed within 12 months of Visit 1 as confirmed by central readers
  • DLCO corrected for (Hb) [visit 1] ≥ 30% and ≤90% of predicted of normal
  • FVC ≥ 45% of predicted normal

Key Exclusion Criteria:

  • Primary obstructive airway physiology (pre-bronchodilator /FVC \< 0.7 at Visit 1)
  • Known explanation for interstitial lung disease, including but not limited to radiation, sarcoidosis, pneumonitis, bronchiolitis obliterans organizing pneumonia, (HIV), viral hepatitis, and cancer
  • Diagnosis of any connective tissue disease, including but not limited to scleroderma/systemic sclerosis, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis
  • Major extrapulmonary physiological restriction (e.g., chest wall abnormality, large pleural effusion)
  • Cardiovascular diseases, any of the following:

    • Uncontrolled hypertension, within 3 months of Visit 1
    • Myocardial infarction within 6 months of Visit 1
    • Unstable cardiac angina within 6 months of Visit 1
  • Prior hospitalization for confirmed COVID-19, acute exacerbation of IPF or any lower respiratory tract infection within 3-months of Visit 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo oral administration

    Drug: Placebo

  • Active comparator
    pirfenidone 801 mg TID

    pirfenidone 801 mg TID oral administration

    Drug: Pirfenidone

  • Experimental
    LYT-100 550 mg TID

    LYT-100 (Deupirfenidone) 550 mg TID oral administration

    Drug: Deupirfenidone

  • Experimental
    LYT-100 825 mg TID

    LYT-100 (Deupirfenidone) 825 mg TID oral administration

    Drug: Deupirfenidone

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of decline in Forced Vital Capacity over 26 weeks (Part A)

    Rate of decline in Forced Vital Capacity (FVC; in mL)

    Time frame: 26 weeks

Secondary outcomes

  1. Forced Vital Capacity (FVC) percent predicted change (Part A)

    FVC percent predicted (FVCpp) change from baseline to Week 26

    Time frame: Baseline to Week 26

  2. Time to hospitalization or mortality (Part A)

    Time to hospitalization or mortality due to respiratory cause through 26 weeks

    Time frame: 26 weeks

  3. Time to Idiopathic Pulmonary Fibrosis (IPF) progression (Part A)

    Time to IPF progression through 26 weeks, as defined by a decline in FVC% of 5% or greater or death

    Time frame: 26 weeks

  4. Forced Vital Capacity (FVC) percent predicted change (Part B)

    FVC percent predicted (FVCpp) change from Week 26 to Week 52

    Time frame: 26 Weeks

  5. Rate of decline in Forced Vital Capacity over 26 weeks (Part B)

    Rate of decline in Forced Vital Capacity (FVC; in mL) from Week 26 to Week 52

    Time frame: 26 Weeks

  6. Time to Idiopathic Pulmonary Fibrosis (IPF) progression (Part B)

    Time to IPF progression from Week 26 to Week 52, as defined by a decline in FVC% of 5% or greater or death

    Time frame: 26 Weeks

07

Study locations

103 sites

Showing the first 100 of 103 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Maher TM, Hamblin MJ, Choi WI, Case AH, Tomos IP, Tzouvelekis AE, Shore JE, Bergna MA, Golod D, Elenko E, Zhang Y, Graham CS, Song JW, Kulkarni T; ELEVATE IPF Investigators (listed in Supplementary Appendix). Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial. Am J Respir Crit Care Med. 2026 Apr 2:aamag155. doi: 10.1093/ajrccm/aamag155. Online ahead of print. PubMed 42085224 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Oct 2024, 26 months.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 26 months is close to that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2022
First posted
Apr 11, 2022
StartActual
Jul 22, 2022
Primary completionActual
Oct 15, 2024
CompletionEst.
Dec 31, 2025
Results delay requested
Oct 9, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05321420
Lead sponsor
PureTech
Responsible party
Sponsor
First posted
Apr 11, 2022
Start date
Jul 22, 2022
Primary completion
Oct 15, 2024
Completion
Dec 31, 2025 (estimated)
Last update
Oct 16, 2025

Study contacts

Camilla Graham, MD
study director · PureTech

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion